Wedmont Private Capital Buys 938 Shares of McKesson Corporation $MCK

Wedmont Private Capital raised its stake in McKesson Corporation (NYSE:MCK) by 36.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,494 shares of the company’s stock after buying an additional 938 shares during the period. Wedmont Private Capital’s holdings in McKesson were worth $3,250,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Investment Research Partners LLC increased its position in shares of McKesson by 0.7% during the fourth quarter. Investment Research Partners LLC now owns 1,624 shares of the company’s stock worth $1,332,000 after acquiring an additional 11 shares during the period. Rosenberg Matthew Hamilton grew its stake in McKesson by 2.8% in the third quarter. Rosenberg Matthew Hamilton now owns 406 shares of the company’s stock worth $347,000 after purchasing an additional 11 shares in the last quarter. Anchyra Partners LLC grew its stake in McKesson by 1.0% in the first quarter. Anchyra Partners LLC now owns 1,174 shares of the company’s stock worth $1,016,000 after purchasing an additional 12 shares in the last quarter. SJS Investment Consulting Inc. increased its holdings in McKesson by 7.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 172 shares of the company’s stock worth $149,000 after purchasing an additional 12 shares during the period. Finally, SMART Wealth LLC raised its position in McKesson by 3.4% during the 1st quarter. SMART Wealth LLC now owns 366 shares of the company’s stock valued at $317,000 after purchasing an additional 12 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Analysts raised their outlook. Barclays increased its price target to $1,000, and Leerink Partners initiated or reiterated a Buy rating, reinforcing the view that McKesson can continue to appreciate. McKesson also carries a consensus “Moderate Buy” recommendation. Barclays raised its target for McKesson stock to USD 1,000.00
• Positive Sentiment: McKesson is expanding its specialty healthcare business. The company is partnering with Clayton, Dubilier & Rice to acquire Option Care Health in a transaction valued at approximately $5.8 billion, including debt. The deal would give McKesson greater exposure to home and alternate-site infusion services, potentially adding growth and strategic diversification. McKesson, CD&R to Acquire Option Care Health
• Neutral Sentiment: The acquisition’s valuation is attracting investor scrutiny. Option Care shareholders are being offered $32.05 per share, a 37% premium, which could accelerate growth but also raises questions about price, financing, execution and integration risks. McKesson Joins $5.8 Billion Option Care Health Acquisition
• Positive Sentiment: Momentum and fundamental screens remain favorable. Zacks highlighted McKesson as a long-term momentum and growth stock, while Wall Street’s average recommendation remains bullish. Its latest reported quarter also exceeded expectations, with EPS of $9.93 and revenue of $105.38 billion.
• Neutral Sentiment: Long-term-return coverage provides context rather than a new catalyst. A review of a decade-long investment illustrates McKesson’s strong historical performance, but it does not directly change current earnings or valuation expectations. If You Invested $1000 in McKesson a Decade Ago

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MCK shares. Barclays increased their price target on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. Bank of America upped their price objective on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. TD Cowen increased their target price on shares of McKesson from $989.00 to $1,006.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Evercore reissued an “outperform” rating and set a $950.00 target price (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $1,015.00 price target on shares of McKesson in a report on Thursday, August 6th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $983.29.

Insider Buying and Selling

In other news, CAO B Jr sold 111 shares of McKesson stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares of the company’s stock, valued at $464,445.45. The trade was a 17.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley Lerman sold 301 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by insiders.

McKesson Trading Up 0.8%

MCK opened at $937.65 on Friday. The firm has a market cap of $109.32 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 1.95 and a beta of 0.30. McKesson Corporation has a 12 month low of $723.68 and a 12 month high of $999.00. The stock has a fifty day moving average price of $885.20 and a 200-day moving average price of $833.76.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. During the same quarter last year, the company earned $8.26 earnings per share. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, equities research analysts forecast that McKesson Corporation will post 44.73 EPS for the current year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st were issued a $0.94 dividend. The ex-dividend date was Tuesday, September 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio (DPR) is 10.06%.

McKesson Company Profile

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.